LGALS3BP

Across TCGA pan-cancer cohorts, LGALS3BP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LGALS3BP data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LGALS3BP Mutation is associated with better overall survival. In most high-consensus cancer types, elevated LGALS3BP expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SKCM and READ are the cancer types where LGALS3BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	1.000	0.722	.013	8	view →
READ	OS	Median	All	0.156	0.692	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LGALS3BP–SKCM (OS)

Open the SKCM breakdown →